Please login to the form below
CAR therapies
This page shows the latest CAR therapies news and features for those working in and with pharma, biotech and healthcare.
Roche bets on T-cell therapies with Adaptimmune deal
CAR-T therapies including Kymriah (tisagenlecleucel). ... Adapatimmune is also involved in CAR-T and early in 2020 signed a deal with Astellas on both CAR-T and TCR allogeneic therapies.
Latest news
-
Kite partners with Shoreline Biosciences to develop allogeneic cell therapies
The combined strength of Kite’s leadership in CAR T-cell therapies and our cutting-edge iPSC platform will potentially accelerate Shoreline’s timeline to the clinic, expand our pipeline opportunities ... Xanthopoulos, co-founder, chairman and chief
-
BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study
The CAR-T therapy also met key secondary endpoints of complete response rate and progression-free survival compared to standard of care, BMS said in a statement. ... These positive interim results build on our commitment to bring CAR-T cell therapies
-
BMS and bluebird bio gain FDA approval for multiple myeloma therapy
Abecma is a CAR T cell therapy approved for pre-treated myeloma patients. ... Samit Hirawat, chief medical officer, BMS said: “CAR T cell therapies have shown transformational potential for the treatment of haematologic malignancies and we, with our
-
bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin
BMS) and monetisation for ex-US milestones and royalties from CAR T cell therapies ide-cel and bb21217.
-
FDA approves BMS’ blood cancer CAR T therapy after delay
Breyanzi joins other approved CAR T therapies on the market from Gilead/Kite and Novartis. ... BMS, Novartis and Gilead/Kite’s respective CAR T therapies all carry a black box warning for neurotoxicity, as well as cytokine release syndrome – an
Kite partners with Shoreline Biosciences to develop allogeneic cell therapies
BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study
BMS and bluebird bio gain FDA approval for multiple myeloma therapy
bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin
FDA approves BMS’ blood cancer CAR T therapy after delay
More from news
Approximately 1 fully matching, plus 95 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
Historically, both large pharmaceutical and small biotechnology companies have relied on both internal and external sourcing of innovative and promising therapies. ... and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers
-
The impact of COVID-19 on clinical trials
impact on the initiation and completion of hundreds of clinical trials involving investigational therapies for many serious diseases. ... Therapy mechanism of action – immunosuppressive therapies and therapies that require complex and prolonged
-
Cortellis Drugs to Watch in 2020 report
Thanks to the CAR construct, the engineered T cells can recognise and attack the CD19-expressing cancer cells. ... This composition could confer efficacy and safety advantages, including fewer adverse effects such as cytokine release syndrome (CRS) and
-
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... We are introducing the international best practices of developing CAR T to our China team and
-
European biotech: a new generation of leaders emerges
year. The promise of the molecule is great, with analysts seeing it as a possible challenge to Novartis and Gilead’s CAR-T therapies. ... This means its clinical outcomes could match those seen in the CAR-Ts, but without the complexity and cost of
Sourcing R&D innovation: why pharma companies need to evolve their business models
The impact of COVID-19 on clinical trials
Cortellis Drugs to Watch in 2020 report
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
European biotech: a new generation of leaders emerges
More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.
Latest appointments
-
Health comms agency emotive hires new cell and gene therapy leader
It is also charged with developing HCP engagement on gene silencing technology and educating on cell therapies such as CAR-T, and the new business unit will provide core expertise in ... He says this will be needed to ensure advanced therapies realise
-
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
Health comms agency emotive hires new cell and gene therapy leader
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
The heavy toll of COVID-19 on cancer patients
For example, all CAR-T cell therapies were paused as intensive care unit beds were needed to help COVID-19 patients recover. ... New therapies that minimize hospital visits may have to be prioritized by pharmaceuticals and MedTech companies.
-
In the precision medicine era, the line between products and services is blurred
Instead, we carried out in-depth interviews with different types of stakeholders who had considerable experience working on early CAR-T therapies and clinical trials. ... Both of these scenarios were true in the case of the CAR-T treatment.
-
Precision paediatrics: Treating patients with CAR-T
It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach. ... This approach can make targeted therapies like CAR-T a reality. A good example at GOSH is in bone marrow transplants.
-
Highlights in haematologic malignancy from ASH 2018
However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).
-
Download our infographic: Addressing the biggest challenges for rare disease communities
Recently these have included advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies.
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- bluebird bio gears up for split
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
- Health For All
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- Accelerating Drug Development Timelines with Big Data Analytics
- A Lucid Group Thirsty Thursday Special: Beautiful Rejects
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US orders 1.4 million more doses of Regeneron antibody cocktail
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Lilly to target difficult-to-treat disease through tie-up with Lycia
- Sanofi/Regeneron bag first approval for Actemra rival sarilumab
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
